Inhibiting the activity of β-amyloid precursor protein cleaving enzyme 1 (BACE1), a rate-limiting enzyme in the generation of Aβ from APP, has been proved to be an effective way to lower Aβ levels in AD [6, 7]. This evidence concerns the gene APP and Alzheimer disease.